Jack County Hospital District adopts FY 2025-2026 budget with focus on capital needs, rural ambulance grants, and managing shifts between Medicare Advantage and traditional Medicare claims.
Smart Medigap Plans broadens Medicare supplement offerings in Texas, enhancing coverage options for Medicare beneficiaries including prescription drug and supplemental insurance.
The looming deadline for drugmakers to comply with the Most Favored Nation drug pricing policy raises concerns over potential disruptions to Medicare Part D, highlighting regulatory and market risks for U.S. drug pricing and federal entitlement programs.
Study shows value-based payment models with two-sided risk improve clinical quality outcomes for Medicare Advantage beneficiaries compared to fee-for-service.
The Trump administration's Medicare pilot introduces AI-driven prior authorization to reduce waste and control costs, raising regulatory and patient care concerns.
Recent legislative changes to Medicare’s drug price negotiation program expand orphan drug exclusions, delaying price negotiation for expensive specialty drugs and increasing costs for Medicare beneficiaries.
Medicare Part D sees near-universal prior authorization and rising out-of-pocket costs for GLP-1 drugs in 2025, reflecting insurer adjustments to new cost and regulatory pressures.
Trilogy Health Services CMO discusses Medicare Advantage's impact on skilled nursing, focusing on administrative challenges, appeals, and value-based care opportunities. Insights on I-SNP partnerships and payment simplification for providers.
Medicare Advantage expansion is linked to care delays in skilled nursing facilities, urging providers to better understand MA protocols for improved patient outcomes.
FDA approves prescription leucovorin for autism treatment; HHS addresses investment and regulatory concerns involving CMS administrator Dr. Mehmet Oz amid public discourse.
